1) In January, Biosensors received CE Mark approval for its polymer-free drug-coated stent (DCS), BioFreedom™ the Company has also commenced global patient enrollment for LEADERS FREE clinical study during the quarter 2) Biosensors has signed an OEM agreement for both coronary and peripheral drug-eluting balloons which will be marketed under Biosensors’ brand name. These products have obtained several regulatory approvals including CE mark and will be available to Biosensors for worldwide distribution 3) Recently, the Company successfully raised S$300 million (approximately US$240 million) from the issuance of 4.875% fixed rate notes due 2017 under its S$800 million Multicurrency Medium Term Note Programme 4) In Q3 FY13, Interventional Cardiology Products (IVP) sales, largely comprising drug-eluting stent (DES) sales, increased by 9% year-on-year. For the FY13 nine-month period, IVP sales grew 42% compared to the same period last year 5) ...
